{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:59:44Z","timestamp":1781639984845,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07799-1","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:44:38Z","timestamp":1773128678000},"page":"4895-4904","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Omitted staging PSMA PET\/CT is associated with advance disease extent at time of PSA persistence: a single center retrospective analysis"],"prefix":"10.1007","volume":"53","author":[{"given":"Andrea","family":"Di Giorgio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Rapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Di Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina Maria Paola","family":"Sgro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giambattista","family":"Siepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Droghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Castellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Schiavina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"3","key":"7799_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"7799_CR2","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fonc.2020.00246","volume":"10","author":"B Chys","year":"2020","unstructured":"Chys B, Devos G, Everaerts W, Albersen M, Moris L, Claessens F, et al. Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. Front Oncol. 2020;10:246.","journal-title":"Front Oncol"},{"key":"7799_CR3","unstructured":"Miller SR, Chung DH, Gonzalez RT, Jackson WC, Caram MEV, Tsao PA et al. Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer. J Nucl Med Off Publ Soc Nucl Med. 2025;jnumed.125.270825."},{"issue":"8","key":"7799_CR4","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1111\/j.1464-410X.2012.11012.x","volume":"110","author":"K Westover","year":"2012","unstructured":"Westover K, Chen MH, Moul J, Robertson C, Polascik T, Dosoretz D, et al. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer. BJU Int. 2012;110(8):1116\u201321.","journal-title":"BJU Int"},{"issue":"11","key":"7799_CR5","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021;7(11):1635\u201342.","journal-title":"JAMA Oncol"},{"issue":"2","key":"7799_CR6","first-page":"146","volume":"13","author":"C Poenateetai","year":"2025","unstructured":"Poenateetai C, Teyateeti A, Pusuwan P, Teyateeti A. Whole-Body Bone Scan for Detecting Bone Metastasis in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era: A Retrospective Cohort Study of Post-Radical Prostatectomy Prostate Cancer Patients. Asia Ocean J Nucl Med Biol. 2025;13(2):146\u201355.","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"7799_CR7","unstructured":"de Bie KCC, Zuur LG, Meijer D, Meijnen P, Hinnen KA, Oprea-Lager DE et al. Oncological Outcomes in Patients with Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography-detected Oligometastatic Prostate Cancer Treated with Metastasis-directed Radiotherapy as the Single Treatment Modality. Eur Urol Oncol. 2025;S2588-9311(25)00090\u2009\u2013\u20092."},{"issue":"10231","key":"7799_CR8","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet Lond Engl. 2020;395(10231):1208\u201316.","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"7799_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, Van Den Bergh RCN, Briers E, Van Den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86(2):148\u201363.","journal-title":"Eur Urol"},{"key":"7799_CR10","doi-asserted-by":"crossref","unstructured":"Bianchi L, Droghetti M, Catanzaro C, Valerio M, Novello Q, Mari A et al. Prostate-specific Membrane Antigen Positron Emission Tomography Versus Conventional Imaging for Preoperative Staging High-risk Prostate Cancer Patients Undergoing Surgery for cN0M0 Disease: An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study. Eur Urol Oncol. 2025;S2588-9311(25)00304-9.","DOI":"10.1016\/j.euo.2025.11.011"},{"key":"7799_CR11","doi-asserted-by":"crossref","unstructured":"Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, et al. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Eur Urol. 2016 June;69(6):1142\u20138.","DOI":"10.1016\/j.eururo.2015.12.010"},{"key":"7799_CR12","unstructured":"Karpinski MJ, Rahbar K, B\u00f6gemann M, Nikoukar LR, Sch\u00e4fers M, Hober\u00fcck S et al. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Eur Urol. 2025;S0302-2838(25)00249-0."},{"issue":"6","key":"7799_CR13","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1097\/JU.0000000000000417","volume":"202","author":"A Farolfi","year":"2019","unstructured":"Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, et al. 68Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. J Urol. 2019;202(6):1174\u201381.","journal-title":"J Urol"},{"key":"7799_CR14","doi-asserted-by":"crossref","unstructured":"Chen Q, Wang W, Wang Y, Dong L, Zhao H, Li L et al. The clinical utility of total-body [68 Ga]Ga-PSMA-11 PET\/CT in prostate cancer: identifying extra-regional bone metastases and informing treatment strategies. Eur J Nucl Med Mol Imaging. 2025.","DOI":"10.1007\/s00259-025-07581-9"},{"issue":"2","key":"7799_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86(2):164\u201382.","journal-title":"Eur Urol"},{"issue":"5","key":"7799_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur Urol. 2023;83(5):405\u201312.","journal-title":"Eur Urol"},{"key":"7799_CR17","unstructured":"Bonaddio J, Carll J, Eapen R, Sathianathen N, Lawrentschuk N. The role of PSMA PET\/CT in staging patients with intermediate-risk prostate cancer. BJU Int. 2025 Sept 30."},{"key":"7799_CR18","unstructured":"Hartwieg BF, Maurer T, Kniep C, Mandel P, Wenzel M, Falkenbach F et al. Use of staging in intermediate-risk prostate cancer: A real-world data analysis. Urol Oncol. 2025;S1078-1439(25)00382-5."},{"issue":"5","key":"7799_CR19","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1001\/jamaoncol.2025.0110","volume":"11","author":"D Tilki","year":"2025","unstructured":"Tilki D, Chen MH, Wu J, Huland H, Graefen M, Trock BJ, et al. Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk. JAMA Oncol. 2025;11(5):502\u201310.","journal-title":"JAMA Oncol"},{"key":"7799_CR20","doi-asserted-by":"crossref","unstructured":"Di Giorgio A, Siepe G, Serani F, Di Franco M, Malizia C, Castellucci P et al. Long-term outcomes of PSMA PET\/CT-guided radiotherapy in biochemical failure patients post-radical prostatectomy: a 5-year follow-up analysis. Eur J Nucl Med Mol Imaging. 2025.","DOI":"10.1007\/s00259-025-07255-6"},{"issue":"10323","key":"7799_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet Lond Engl. 2022;399(10323):447\u201360.","journal-title":"Lancet Lond Engl"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07799-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07799-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07799-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:44:04Z","timestamp":1781639044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07799-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7799"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07799-1","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"8 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author Andrea Di Giorgio, Marco Rapa, Martina Di Franco, Caterina Maria Paolo Sgro, Giambattista Siepe, Veronica Mollica, Lorenzo Bianchi, Matteo Droghetti, Riccardo Schiavina, Riccardo Mei and Andrea Farolfi declare they have no financial interests. Paolo Castellucci received consulting fees, travel fees, or honoraria from Novartis, Curium, Recordati, Astra Zeneca. Stefano Fanti reports, outside the submitted work, personal honoraria from Novartis and personal fees from AAA, Amgen, Astellas, Bayer, Debio, GE Healthcare, Immedica, Janssen, Sofie, and Telix.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trial Registration"}}]}}